Why are there no approved treatments for cognitive impairment in schizophrenia?

doi:10.1002/wps.20648

. 2019 Jun;18(2):167-168.

doi: 10.1002/wps.20648.

Why are there no approved treatments for cognitive impairment in schizophrenia?

Richard S E Keefe¹

Affiliations

PMID: 31059617
PMCID: PMC6502426
DOI: 10.1002/wps.20648

Why are there no approved treatments for cognitive impairment in schizophrenia?

Richard S E Keefe. World Psychiatry. 2019 Jun.

. 2019 Jun;18(2):167-168.

doi: 10.1002/wps.20648.

Author

Richard S E Keefe¹

Affiliation

¹ Department of Psychiatry, Duke University Medical Center, Durham, NC, USA.

PMID: 31059617
PMCID: PMC6502426
DOI: 10.1002/wps.20648

No abstract available

PubMed Disclaimer

Cited by

Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853).
Palumbo D, Caporusso E, Piegari G, Mencacci C, Torriero S, Giuliani L, Fabrazzo M, Pinto D, Galderisi S. Palumbo D, et al. Front Psychiatry. 2022 Apr 4;13:833550. doi: 10.3389/fpsyt.2022.833550. eCollection 2022. Front Psychiatry. 2022. PMID: 35444577 Free PMC article.
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.
Rosenbrock H, Desch M, Wunderlich G. Rosenbrock H, et al. Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36971864 Free PMC article. Review.
Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities.
Nuechterlein KH, Nasrallah H, Velligan D. Nuechterlein KH, et al. Schizophr Bull. 2025 Mar 14;51(2):401-421. doi: 10.1093/schbul/sbae051. Schizophr Bull. 2025. PMID: 39088730 Free PMC article. Review.
How Functional Connectivity Measures Affect the Outcomes of Global Neuronal Network Characteristics in Patients with Schizophrenia Compared to Healthy Controls.
Jonak K, Marchewka M, Podkowiński A, Siejka A, Plechawska-Wójcik M, Karpiński R, Krukow P. Jonak K, et al. Brain Sci. 2023 Jan 13;13(1):138. doi: 10.3390/brainsci13010138. Brain Sci. 2023. PMID: 36672119 Free PMC article.
Long-Term Benzodiazepine Prescription During Maintenance Therapy of Individuals With Psychosis Spectrum Disorders-Associations With Cognition and Global Functioning.
Savić B, Jerotić S, Ristić I, Zebić M, Jovanović N, Russo M, Marić NP. Savić B, et al. Clin Neuropharmacol. 2021 May-Jun 01;44(3):89-93. doi: 10.1097/WNF.0000000000000442. Clin Neuropharmacol. 2021. PMID: 33560008 Free PMC article.

See all "Cited by" articles

References

1. Green MF, Horan WP, Lee J. World Psychiatry 2019;18:146‐61. - PMC - PubMed
1. NIH Research Portfolio Online Reporting Tools. NIH categorical spending. https://report.nih.gov.
1. McClung T. PhRMA member companies R&D investments hit record high in 2017 – $71.4 billion. https://catalyst.phrma.org.
1. US National Library of Medicine . ClinicalTrials.gov. https://clinicaltrials.gov. - PubMed
1. Thomas DW, Burns J, Audette J et al. Clinical development success rates 2006‐2015. Washington: Biotechnology Innovation Organization, 2016.

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov

[1] Green MF, Horan WP, Lee J. World Psychiatry 2019;18:146‐61. - PMC - PubMed

[2] Green MF, Horan WP, Lee J. World Psychiatry 2019;18:146‐61. - PMC - PubMed

[3] NIH Research Portfolio Online Reporting Tools. NIH categorical spending. https://report.nih.gov.

[4] NIH Research Portfolio Online Reporting Tools. NIH categorical spending. https://report.nih.gov.

[5] McClung T. PhRMA member companies R&D investments hit record high in 2017 – $71.4 billion. https://catalyst.phrma.org.

[6] McClung T. PhRMA member companies R&D investments hit record high in 2017 – $71.4 billion. https://catalyst.phrma.org.

[7] US National Library of Medicine . ClinicalTrials.gov. https://clinicaltrials.gov. - PubMed

[8] US National Library of Medicine . ClinicalTrials.gov. https://clinicaltrials.gov. - PubMed

[9] Thomas DW, Burns J, Audette J et al. Clinical development success rates 2006‐2015. Washington: Biotechnology Innovation Organization, 2016.

[10] Thomas DW, Burns J, Audette J et al. Clinical development success rates 2006‐2015. Washington: Biotechnology Innovation Organization, 2016.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Why are there no approved treatments for cognitive impairment in schizophrenia?

Affiliation

Why are there no approved treatments for cognitive impairment in schizophrenia?

Author

Affiliation

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Medical